Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1165-1170

  Ribas, Antoni ^a   Bui, Lynne A ^a   Butterfield, Lisa H ^a   Vollmer, Charles M ^a   Jilani, Syed M ^a   Dissette, Vivian B ^a   Glaspy, John A ^a   Mcbride, William H ^a   Economou, James S ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cells; Immunotherapy; Interleukin 2; Tumor peptides

Indexed keywords

INTERLEUKIN 2; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENETIC ENGINEERING; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TUMOR GROWTH; VACCINATION;

ACIDS; ANIMALS; DENDRITIC CELLS; FEMALE; IMMUNIZATION; INTERLEUKIN-2; MICE; MICE, INBRED C3H; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL;

EID: 0033034555     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rammensee HG, Falk K, Rotzschke O: MHC molecules as peptide receptors. Curr Opin Immunol 5: 35, 1993.
2. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82: 13, 1995.
3. Loftus DJ, Kubo RT, Sakaguchi K, Cells E, Sette A, Appella E: Analysis of MHC-specific peptide motifs. Applications in immunotherapy. Adv Exp Med Biol 383: 201, 1995.
4. Bellone M, Iezzi G, Manfredi AA, Protti MP, Dellabona P, Casorati G, Rugarli C: In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol 24: 2691, 1994.
5. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183: 283, 1996.
6. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1: 1297, 1995.
7. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183: 1357, 1996.
8. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156: 2918, 1996.
9. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J ExpMed 183: 317, 1996.
10. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255, 1995.
11. Sugawara S, Abo T, Kumagai K: A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. J Immunol Methods 100: 83, 1987
12. Storkus WJ, Zeh HJd, Salter RD, Lotze MT: Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 14: 94, 1993.
13. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183: 87, 1996.
14. Nair SK, Snyder D, Rouse BT, Gilboa E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70: 706, 1997.
15. Milas L, Wike J, Hunter N, Volpe J, Basic I: Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res 47: 1069, 1987.
16. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693, 1992.
17. Ribas A, Butteffield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS: Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 57: 2865, 1997.
18. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S, Rhoades K, Drake T, Belldegrun A, Glaspy J, Economou JS: In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 3: 11, 1996.
19. Nair SK, Boczkowski D, Snyder D, Gilboa E: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27: 589, 1997.
20. Yang S, Darrow TL, Vervaert CE, Seigler HF: Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell Immunol 179: 84, 1997.